{"groups":[{"description":"Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression\n\nIntervention: Drug: melphalan 5mg/m\\^2 orally days 1-4 every 28 days until progression\n\nIntervention: Drug: prednisone 60mg/m\\^2, orally days 1-4 every 28 days until progression","id":"FG000","title":"Treatment (Lenalidomide, Melphalan, Prednisone)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Currently Receiving Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This was as Phase I/II trial. There were 7 patients recruited to the Phase I portion; no patients qualified for the Phase II portion. Twenty-six (26) patients were recruited for the Phase II portion. Results presented here are on the 26 Phase II patients."}